Výsledky vyhľadávania - "Neoplasms/drug therapy"

Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy

Autori: Braybrooke, Jeremy Bradley, Rosie Hills, Robert K a ďalší

Prispievatelia: Braybrooke, Jeremy Bradley, Rosie Hills, Robert K a ďalší

Zdroj: Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Electronic address: bc.overview@ndph.ox.ac.uk, Clarke, M & McIntosh, S A 2025, 'Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy', Lancet (London, England), vol. 406, no. 10503, pp. 603-614. https://doi.org/10.1016/S0140-6736(25)01013-X

Predmety: [STAT.ME] Statistics [stat]/Methodology [stat.ME], antineoplastic agents, hormonal/administration & dosage, randomized controlled trials as topic, [STAT.OT] Statistics [stat]/Other Statistics [stat.ML], breast neoplasms/drug therapy, [STAT] Statistics [stat], postmenopause, aged, female, [SDV.CAN] Life Sciences [q-bio]/Cancer, aromatase inhibitors/administration & dosage, neoplasm recurrence, local/prevention & control, tamoxifen/administration & dosage, middle aged, [SHS.STAT] Humanities and Social Sciences/Methods and statistics, chemotherapy, adjuvant, name=SDG 3 - Good Health and Well-being, humans

Popis súboru: application/pdf

Prístupová URL adresa: https://inserm.hal.science/inserm-05224587v1/document
https://doi.org/10.1016/s0140-6736(25)01013-x
https://inserm.hal.science/inserm-05224587v1
https://pure.qub.ac.uk/en/publications/75848c25-50e8-44e9-b387-c46d343e6acc
https://hdl.handle.net/11567/1263299
https://doi.org/10.1016/S0140-6736(25)01013-X

Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?

Autori: Decruyenaere, Alexander Gennigens, Christine Sylvie, Rottey a ďalší

Prispievatelia: Decruyenaere, Alexander Gennigens, Christine Sylvie, Rottey a ďalší

Zdroj: Acta Oncologica, Vol 64 (2025)
Acta oncologica
ACTA ONCOLOGICA

Predmety: Male, Immune Checkpoint Inhibitors/administration & dosage, Radiology, Nuclear Medicine and Imaging, Time Factors, Oncologie, THERAPY, Carcinoma, Renal Cell/secondary, immune checkpoint inhibitors, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Ipilimumab/administration & dosage, Human health sciences, Kidney Neoplasms/mortality, Immune Checkpoint Inhibitors, RC254-282, Aged, 80 and over, OUTCOMES, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Carcinoma, Renal Cell/pathology, Hematology, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Kidney Neoplasms, Progression-Free Survival, Renal cell carcinoma, Nivolumab/administration & dosage, treatment discontinuation, Carcinoma, Renal Cell/mortality, Kidney Neoplasms/drug therapy, Nivolumab, optimal treatment duration, Oncology, Female, Life Sciences & Biomedicine, Adult, DISCONTINUATION, Sciences de la santé humaine, Kidney Neoplasms/pathology, Immune Checkpoint Inhibitors/adverse effects, 3211 Oncology and carcinogenesis, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Carcinoma, Renal Cell, Retrospective Studies, Aged, Science & Technology, Duration of Therapy, Immune Checkpoint Inhibitors/therapeutic use, Ipilimumab, MELANOMA PATIENTS, Carcinoma, Renal Cell/drug therapy, Human medicine, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Follow-Up Studies

Popis súboru: application/pdf

Prístupová URL adresa: https://doaj.org/article/f0b66be9934249d38e034df42f696b62
https://hdl.handle.net/2268/335276
https://doi.org/10.2340/1651-226X.2025.43876
https://repository.uantwerpen.be/docstore/d:irua:30312
https://hdl.handle.net/10067/2161490151162165141
http://hdl.handle.net/1942/46632
http://hdl.handle.net/1854/LU-01K3QQRTE94KZYP1CX1X0WZ5CD
https://biblio.ugent.be/publication/01K3QQRTE94KZYP1CX1X0WZ5CD/file/01K42SV66F3YD38FGWT899GJ86
https://biblio.ugent.be/publication/01K3QQRTE94KZYP1CX1X0WZ5CD
http://doi.org/10.2340/1651-226x.2025.43876

Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors

Autori: Zakile A. Mfumbilwa Janneke A. Wilschut Harry J. M. Groen a ďalší

Zdroj: Clin Drug Investig

Predmety: Male, Cost-Benefit Analysis, Carcinoma, B7-H1 Antigen/antagonists & inhibitors, Non-Small-Cell Lung/drug therapy, Antineoplastic Agents, Immunological/economics, Antibodies, SDG 3 - Good Health and Well-being, Monoclonal, Humanized/economics, Humans, Female, Quality-Adjusted Life Years, Original Research Article, Lung Neoplasms/drug therapy, Netherlands

Prístupová URL adresa: https://pure.eur.nl/en/publications/e2bf9f5e-4943-4cee-92bf-5cf33fdca748
https://doi.org/10.1007/s40261-025-01456-5
https://hdl.handle.net/11370/8333e2bb-12cd-477b-a176-07f41d2f1f51
https://doi.org/10.1007/s40261-025-01456-5
https://research.rug.nl/en/publications/8333e2bb-12cd-477b-a176-07f41d2f1f51
https://pure.amsterdamumc.nl/en/publications/b5e4d0c1-f19d-45da-af70-69599a6de844
https://doi.org/10.1007/s40261-025-01456-5

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Autori: Uppaluri, Ravindra Haddad, Robert I Tao, Yungan a ďalší

Zdroj: New England Journal of Medicine. 393:37-50

Predmety: Adult, Male, Antibodies, Monoclonal, Humanized / adverse effects, Antibodies, Monoclonal, Humanized / administration & dosage, Young Adult, Chemotherapy, Adjuvant / methods, B7-H1 Antigen / analysis, B7-H1 Antigen / antagonists & inhibitors, Humans, Neoadjuvant Therapy / adverse effects, Antineoplastic Agents, Immunological / administration & dosage, Antineoplastic Agents, Immunological / adverse effects, Aged, Aged, 80 and over, Head and Neck Neoplasms / mortality, Head and Neck Neoplasms / pathology, Squamous Cell Carcinoma of Head and Neck / pathology, Middle Aged, Head and Neck Neoplasms / drug therapy, Neoadjuvant Therapy / methods, Progression-Free Survival, Squamous Cell Carcinoma of Head and Neck / surgery, Intention to Treat Analysis, B7-H1 Antigen / metabolism, Treatment Outcome, Head and Neck Neoplasms / surgery, Squamous Cell Carcinoma of Head and Neck / drug therapy, Female, Chemotherapy, Adjuvant / adverse effects, Squamous Cell Carcinoma of Head and Neck / mortality

Popis súboru: application/pdf

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer

Autori: Elena Elez Takayuki Yoshino Lin Shen a ďalší

Zdroj: N Engl J Med
Elez, E, BREAKWATER Trial Investigators & Poulsen, L Ø 2025, 'Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer', The New England Journal of Medicine, vol. 392, no. 24, pp. 2425-2437. https://doi.org/10.1056/NEJMoa2501912

Predmety: Adult, Male, Organoplatinum Compounds, Leucovorin, Cetuximab/adverse effects, Article, Young Adult, Carbamates/administration & dosage, Neoplasm Metastasis/drug therapy, Humans, Proto-Oncogene Proteins B-raf/antagonists & inhibitors, Treatments in Oncology, Aged, Aged, 80 and over, Sulfonamides/administration & dosage, Gastroenterology, Colorectal Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Hematology/Oncology, Progression-Free Survival, Treatment Outcome, Mutation, Female, Fluorouracil, Gastrointestinal Tract Cancer

Prístupová URL adresa: http://www.scopus.com/inward/record.url?scp=105009834683&partnerID=8YFLogxK
https://doi.org/10.1056/NEJMoa2501912
https://pmc.ncbi.nlm.nih.gov/articles/PMC12197837/pdf/nihms-2071508.pdf
https://vbn.aau.dk/da/publications/78e1b9c2-1743-44a4-8c52-05389d9e3026

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial

Autori: Pasi A. Jänne Bin-Chao Wang Byoung Chul Cho a ďalší

Zdroj: J Clin Oncol
Journal of clinical oncology, vol. 43, no. 13, pp. 1553-1563

Predmety: Male, Adult, Aged, 80 and over, Lung Neoplasms, Aniline Compounds, Indoles, ORIGINAL REPORTS, Pemetrexed, Exons, Middle Aged, Progression-Free Survival, Carboplatin, ErbB Receptors, Pyrimidines, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carboplatin/administration & dosage, Carboplatin/adverse effects, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/genetics, Carcinoma, Non-Small-Cell Lung/pathology, Carcinoma, Non-Small-Cell Lung/enzymology, Cisplatin/administration & dosage, Cisplatin/adverse effects, ErbB Receptors/genetics, ErbB Receptors/antagonists & inhibitors, Lung Neoplasms/drug therapy, Lung Neoplasms/genetics, Lung Neoplasms/pathology, Lung Neoplasms/enzymology, Pemetrexed/administration & dosage, Pemetrexed/adverse effects, Protein Kinase Inhibitors/therapeutic use, Protein Kinase Inhibitors/adverse effects, Cisplatin, Protein Kinase Inhibitors

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39879577
https://serval.unil.ch/notice/serval:BIB_F1541B0B9B82
https://serval.unil.ch/resource/serval:BIB_F1541B0B9B82.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_F1541B0B9B821

Osimertinib: A Game-Changer in Stage IV EGFR-Driven Lung Cancer

Autori: Sofia Silva Joana Duarte Carla Simão a ďalší

Zdroj: Acta Médica Portuguesa (2025)

Predmety: ErbB Receptors, Medicine (General), R5-920, Carcinoma, Non-Small-Cell Lung/drug therapy, Medicine, Lung Neoplasms/drug therapy, Osimertinib

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/40214407
https://doaj.org/article/efa7c3e7bd3240b8878b7f8ca6318c29

Survival Without Quality of Life Deterioration in the GORTEC 2014-04 'OMET' Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR

Autori: Juliette Thariat Mathieu Bosset Antoine Falcoz a ďalší

Prispievatelia: Juliette Thariat Mathieu Bosset Antoine Falcoz a ďalší

Zdroj: International journal of radiation oncology, biology, physics, vol. 121, no. 5, pp. 1194-1206

Predmety: Humans, Quality of Life, Radiosurgery/methods, Radiosurgery/mortality, Male, Female, Middle Aged, Head and Neck Neoplasms/mortality, Head and Neck Neoplasms/pathology, Head and Neck Neoplasms/therapy, Head and Neck Neoplasms/radiotherapy, Head and Neck Neoplasms/drug therapy, Aged, Neoplasm Metastasis, Cetuximab/administration & dosage, Cetuximab/therapeutic use, Fluorouracil/administration & dosage, Squamous Cell Carcinoma of Head and Neck/mortality, Squamous Cell Carcinoma of Head and Neck/therapy, Squamous Cell Carcinoma of Head and Neck/secondary, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Adult, Survival Rate

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39612953
https://serval.unil.ch/resource/serval:BIB_F3A45574859E.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_F3A45574859E1
https://serval.unil.ch/notice/serval:BIB_F3A45574859E

Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief Report

Autori: Daniele Tavernari Maxime Borgeaud Ximeng Liu a ďalší

Zdroj: Journal of thoracic oncology, vol. 20, no. 4, pp. 500-506

Predmety: Uncommon EGFR mutations, Male, Adult, Aged, 80 and over, Lung Neoplasms, Humans, Female, ErbB Receptors/genetics, Mutation, Lung Neoplasms/genetics, Lung Neoplasms/pathology, Lung Neoplasms/drug therapy, Carcinoma, Non-Small-Cell Lung/genetics, Carcinoma, Non-Small-Cell Lung/pathology, Carcinoma, Non-Small-Cell Lung/drug therapy, Middle Aged, Aged, Co-mutations, Compound EGFR mutations, EGFR, Non–small-cell lung cancer, ErbB Receptors, Carcinoma, Non-Small-Cell Lung

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39694414
https://archive-ouverte.unige.ch/unige:183984
https://doi.org/10.1016/j.jtho.2024.12.012
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_55E39726C98A3
https://serval.unil.ch/notice/serval:BIB_55E39726C98A
https://serval.unil.ch/resource/serval:BIB_55E39726C98A.P001/REF.pdf

Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy

Autori: Daoudlarian, D. Segot, A. Latifyan, S. a ďalší

Zdroj: Annals of oncology, vol. 36, no. 4, pp. 444-459

Predmety: Humans, Antibodies, Monoclonal, Humanized/therapeutic use, Female, Male, Retrospective Studies, Middle Aged, Cytokine Release Syndrome/drug therapy, Cytokine Release Syndrome/immunology, Cytokine Release Syndrome/blood, Cytokine Release Syndrome/diagnosis, Cytokine Release Syndrome/chemically induced, Aged, Immune Checkpoint Inhibitors/adverse effects, Lymphohistiocytosis, Hemophagocytic/immunology, Lymphohistiocytosis, Hemophagocytic/drug therapy, Lymphohistiocytosis, Hemophagocytic/diagnosis, Lymphohistiocytosis, Hemophagocytic/chemically induced, Lymphohistiocytosis, Hemophagocytic/blood, Neoplasms/drug therapy, Neoplasms/immunology, Adult, Aged, 80 and over, Sepsis/immunology, Sepsis/diagnosis, Sepsis/drug therapy, Sepsis/blood, Biomarkers/blood, Cytokines/blood, biomarkers, cytokine release syndrome, hemophagocytic lymphohistiocytosis, immune checkpoint inhibitors, immune profiling, sepsis

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39701282
https://serval.unil.ch/resource/serval:BIB_6B38C9E34CAB.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_6B38C9E34CAB
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_6B38C9E34CAB0

Asparagine deprivation enhances T cell antitumour response in patients via ROS-mediated metabolic and signal adaptations

Autori: Hsuan-Chia Chang Chung-Ying Tsai Cheng-Lung Hsu a ďalší

Zdroj: Nat Metab
Nature metabolism, vol. 7, no. 5, pp. 918-927

Predmety: Humans, Asparagine/deficiency, Asparagine/metabolism, Asparaginase/therapeutic use, Asparaginase/pharmacology, Reactive Oxygen Species/metabolism, Nasopharyngeal Carcinoma/drug therapy, Nasopharyngeal Carcinoma/immunology, Nasopharyngeal Carcinoma/metabolism, CD8-Positive T-Lymphocytes/immunology, CD8-Positive T-Lymphocytes/metabolism, CD8-Positive T-Lymphocytes/drug effects, Signal Transduction/drug effects, T-Lymphocytes/immunology, T-Lymphocytes/metabolism, T-Lymphocytes/drug effects, Nasopharyngeal Neoplasms/drug therapy, Nasopharyngeal Neoplasms/immunology, Nasopharyngeal Neoplasms/metabolism, Brief Communication

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/40045118
https://serval.unil.ch/resource/serval:BIB_CA5792C804FD.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_CA5792C804FD
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_CA5792C804FD8

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors

Autori: Valentina Gambardella Michael Ong Maria E. Rodriguez-Ruiz a ďalší

Prispievatelia: Valentina Gambardella Michael Ong Maria E. Rodriguez-Ruiz a ďalší

Zdroj: Cancer Res Commun
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Gambardella, V, Ong, M, Rodriguez-Ruiz, M E, Machiels, J-P, Sanmamed, M F, Galvao, V, Spreafico, A, Renouf, D J, Luen, S J, Galot, R, de Spéville, B D, Calvo, E, Naing, A, Curdt, S, Kolben, T M, Rossmann, E, Tanos, T, Smart, K, Amann, M, Xie, Y, Xu, L, Alcaide, E G, Städler, N, Justies, N, Boetsch, C, Karanikas, V, Schnetzler, G & Rohrberg, K S 2025, ' Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors ', Cancer research communications, vol. 5, no. 3, pp. 422-432 . https://doi.org/10.1158/2767-9764.CRC-24-0638

Predmety: Male, Adult, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Toxicity Tests::Maximum Tolerated Dose, Maximum Tolerated Dose, Other subheadings::Other subheadings::/therapeutic use, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Interleukin-2 Receptor alpha Subunit/metabolism, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::pruebas de toxicidad::dosis máxima tolerada, Otros calificadores::Otros calificadores::/uso terapéutico, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, Antineoplastic Combined Chemotherapy Protocols/pharmacology, Antibodies, Monoclonal, Humanized, T-Lymphocytes, Regulatory, Quimioteràpia combinada, DISEASES::Neoplasms, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Aged, Aged, 80 and over, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, Càncer - Tractament, Interleukin-2 Receptor alpha Subunit, Middle Aged, Neoplasms/drug therapy, T-Lymphocytes, Regulatory/drug effects, Antibodies, Monoclonal, Humanized/therapeutic use, ENFERMEDADES::neoplasias, Female, Research Article

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39983024
http://hdl.handle.net/11351/12929
https://curis.ku.dk/ws/files/432481489/crc_24_0638.pdf

ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update: 2023 update

Autori: Cherny, N I Trapani, D Galotti, M a ďalší

Zdroj: Annals of Oncology. 36:247-262

Predmety: Antineoplastic Agents/economics, Drugs, Antineoplastic Agents, Global Health, Health Services Accessibility, Neoplasms/drug therapy, Health Expenditures/statistics & numerical data, Health Services Accessibility/economics, Essential/economics, Neoplasms, Surveys and Questionnaires, Humans, Global Health/economics, Health Expenditures, Drugs, Essential

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39818519

Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study: 5-year follow-up from the randomized phase III KEYNOTE-177 study

Autori: André, T. Shiu, K. K. Kim, T. W. a ďalší

Prispievatelia: André, T. Shiu, K. K. Kim, T. W. a ďalší

Zdroj: Annals of Oncology. 36:277-284

Predmety: Male, Adult, mismatch repair deficient, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, DNA Mismatch Repair, Antibodies, Antineoplastic Agents, Immunological, Immunological/therapeutic use, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Humans, Aged, Aged, 80 and over, Bevacizumab/administration & dosage, microsatellite instability high, metastatic colorectal cancer, Colorectal Neoplasms/drug therapy, Hematology, Middle Aged, Progression-Free Survival, Bevacizumab, Oncology, Humanized/administration & dosage, Microsatellite Instability, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, pembrolizumab, Colorectal Neoplasms, Follow-Up Studies

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39631622
https://dspace.library.uu.nl/handle/1874/460498
https://pure.amsterdamumc.nl/en/publications/4310d59d-60c1-4096-a069-4c4810203700
https://doi.org/10.1016/j.annonc.2024.11.012

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study

Autori: Mark Schuiveling Laurens S Ter Maat Isabella A J Van Duin a ďalší

Zdroj: J Natl Cancer Inst
Journal of the National Cancer Institute, 117, 6, pp. 1245-1252
Journal of the National Cancer Institute, vol. 117, no. 6, pp. 1245-1252

Predmety: Humans, Melanoma/drug therapy, Melanoma/mortality, Melanoma/pathology, Male, Female, Immune Checkpoint Inhibitors/therapeutic use, Body Composition, Middle Aged, Aged, Body Mass Index, Retrospective Studies, Tomography, X-Ray Computed, Adult, Treatment Outcome, Progression-Free Survival, Aged, 80 and over, Netherlands/epidemiology, Skin Neoplasms/drug therapy, Skin Neoplasms/mortality, Skin Neoplasms/pathology, Intra-Abdominal Fat, Muscle, Skeletal/diagnostic imaging, Subcutaneous Fat, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Medical Oncology - Radboud University Medical Center, Article

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39980388
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/320183
https://doi.org/10.1093/jnci/djaf039
https://repository.ubn.ru.nl//bitstream/handle/2066/320183/320183.pdf
https://hdl.handle.net/2066/320183
https://serval.unil.ch/notice/serval:BIB_3415CBA985BE
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_3415CBA985BE8
https://serval.unil.ch/resource/serval:BIB_3415CBA985BE.P001/REF.pdf

Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back

Autori: Mariniello, Annapaola Borgeaud, Maxime Weiner, Marc a ďalší

Zdroj: BioDrugs

Predmety: Tumor Microenvironment / drug effects, Immune Checkpoint Inhibitors / pharmacology, Lung Neoplasms / immunology, Immune Checkpoint Inhibitors / therapeutic use, Review Article, Carcinoma, Non-Small-Cell Lung / immunology, Tumor Microenvironment / immunology, Lung Neoplasms / drug therapy, Programmed Cell Death 1 Receptor / antagonists & inhibitors, Immunotherapy / methods, Drug Resistance, Neoplasm, Animals, Humans, Carcinoma, Non-Small-Cell Lung / drug therapy

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39954220
https://archive-ouverte.unige.ch/unige:183990
https://doi.org/10.1007/s40259-024-00700-2

Evaluating the benefits of immunotherapy in metastatic cervical cancer: an observational retrospective analysis

Autori: Ana Isabel Martín-Quesada Lina Pérez-Mendez Natalia Dolores Pérez-Rodríguez

Zdroj: Clin Transl Oncol
Clinical & translational oncology, vol. 27, no. 8, pp. 3535-3542

Predmety: Brief Research Article, Humans, Female, Uterine Cervical Neoplasms/pathology, Uterine Cervical Neoplasms/drug therapy, Uterine Cervical Neoplasms/mortality, Uterine Cervical Neoplasms/therapy, Retrospective Studies, Middle Aged, Aged, Immunotherapy/methods, Adult, Progression-Free Survival, Antibodies, Monoclonal, Humanized/therapeutic use, Longitudinal Studies, B7-H1 Antigen/analysis, Immune Checkpoint Inhibitors/therapeutic use, Aged, 80 and over, Antineoplastic Agents, Immunological/therapeutic use, Cervical Cancer, Immunotherapy, Metastatic, Objective-Response-Rate, Progression-Free-Survival, Real-World-Evidence, Recurrent

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39921802
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_F9D31B2ABC881
https://serval.unil.ch/resource/serval:BIB_F9D31B2ABC88.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_F9D31B2ABC88

Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial: Final Analysis of the Randomized DBCG 07-READ Trial

Autori: Maj-Britt Jensen Eva Balslev Ann Søegaard Knoop a ďalší

Zdroj: Jensen, M-B, Balslev, E, Knoop, A S, Tuxen, M K, Højris, I, Jakobsen, E H, Cold, S, Danø, H, Glavicic, V, Kenholm, J & Ejlertsen, B 2024, ' Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer : Final Analysis of the Randomized DBCG 07-READ Trial ', Journal of Clinical Oncology, vol. 43, no. 4, pp. 373-380 . https://doi.org/10.1200/JCO.24.00836
Jensen, M B, Balslev, E, Knoop, A S, Tuxen, M K, Højris, I, Jakobsen, E H, Cold, S, Danø, H, Glavicic, V, Kenholm, J & Ejlertsen, B 2025, 'Adjuvant Docetaxel and Cyclophosphamide with or Without Epirubicin for Early Breast Cancer : Final Analysis of the Randomized DBCG 07-READ Trial', Journal of Clinical Oncology, vol. 43, no. 4, pp. 373-380. https://doi.org/10.1200/JCO.24.00836

Predmety: Adult, Docetaxel/administration & dosage, Epirubicin/administration & dosage, Breast Neoplasms, Docetaxel, Middle Aged, Disease-Free Survival, Cyclophosphamide/administration & dosage, Breast Neoplasms/drug therapy, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Humans, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cyclophosphamide, Adjuvant, Epirubicin, Aged

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39442040
https://curis.ku.dk/ws/files/430094059/Adjuvant_Docetaxel.pdf
https://portal.findresearcher.sdu.dk/da/publications/27b797ca-a9fe-4f45-af0e-b7c36607686a
https://doi.org/10.1200/JCO.24.00836
https://pure.au.dk/portal/en/publications/8f0d7f02-fcc1-4c1c-9484-81b67d6577ab
https://doi.org/10.1200/JCO.24.00836
http://www.scopus.com/inward/record.url?scp=85208218487&partnerID=8YFLogxK

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Autori: Peters, Solange Paz-Ares, Luis G. Reck, Martin a ďalší

Prispievatelia: Peters, Solange Paz-Ares, Luis G. Reck, Martin a ďalší

Zdroj: Digital.CSIC. Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Journal of thoracic oncology, vol. 20, no. 1, pp. 94-108

Predmety: PD-L1, Nivolumab, Non–small cell lung cancer, Humans, Nivolumab/pharmacology, Nivolumab/therapeutic use, Nivolumab/administration & dosage, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/pathology, Carcinoma, Non-Small-Cell Lung/mortality, Lung Neoplasms/drug therapy, Lung Neoplasms/pathology, Lung Neoplasms/mortality, Lung Neoplasms/metabolism, Ipilimumab/pharmacology, Ipilimumab/therapeutic use, Ipilimumab/administration & dosage, Male, Female, Middle Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, B7-H1 Antigen/metabolism, Aged, Adult, Survival Rate, Aged, 80 and over, Follow-Up Studies, Immunotherapy, Ipilimumab

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39369790
http://hdl.handle.net/10261/390933
https://api.elsevier.com/content/abstract/scopus_id/85208360083
https://serval.unil.ch/resource/serval:BIB_89D370D6F09D.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_89D370D6F09D
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_89D370D6F09D7

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial

Autori: Lopez, Juanita Powles, Thomas Braiteh, Fadi a ďalší

Prispievatelia: Lopez, Juanita Powles, Thomas Braiteh, Fadi a ďalší

Zdroj: Nat Med
NATURE MEDICINE

Predmety: atezolizumab, Male, Adult, INCREASES, Medizin, Oncologie, VACCINE, CD8-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes/immunology, Antibodies, Monoclonal, Humanized, THERAPY, Neoplasms/pathology, Sciences de la santé humaine, Article, Antigens, Neoplasm, Neoplasms, Neoplasms/immunology, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Journal Article, Humans, HETEROGENEITY, Human health sciences, Antigens, Neoplasm/immunology, Aged, Aged, 80 and over, Cancer och onkologi, Biochemistry, Genetics and Molecular Biology (all), CTLA-4 BLOCKADE, Biology and Life Sciences, Middle Aged, CANCER, CD8-Positive T-Lymphocytes/drug effects, Neoplasms/drug therapy, Antibodies, Monoclonal, Humanized/therapeutic use, Oncology, Cancer and Oncology, CELLS, Immunotherapy/methods, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Immunotherapy, Antibodies, Monoclonal, Humanized/administration & dosage

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39762422
https://dspace.library.uu.nl/handle/1874/460017
https://hdl.handle.net/2268/328378
https://doi.org/10.1038/s41591-024-03334-7
https://biblio.ugent.be/publication/01JQNPTCN4PKBW9FWBK5R9XS5W/file/01JQNVF8RNY77SZSGTDWKT746H
http://doi.org/10.1038/s41591-024-03334-7
http://hdl.handle.net/1854/LU-01JQNPTCN4PKBW9FWBK5R9XS5W
https://biblio.ugent.be/publication/01JQNPTCN4PKBW9FWBK5R9XS5W
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-555329
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85214121815
https://www.ncbi.nlm.nih.gov/pubmed/39762422
https://doi.org/10.1038/s41591-024-03334-7